Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14358174 | 0.83 | ALDH1A1 (0.48) | ALDH1A1CYP2C9CYP2C19PTGS2GLA | |
| SCHEMBL15052735 | 0.83 | PTGS2 (0.55) | ALDH1A1CYP2C9CYP2C19PTGS2GLA | |
| SCHEMBL29879191 | 0.83 | ALDH1A1 (0.48) | ALDH1A1CYP2C9CYP2C19PTGS2GLA | |
| SCHEMBL2116437 | 0.77 | PTGS2 (0.66) | ALDH1A1CYP2C9CYP2C19PTGS2GLA | |
| SCHEMBL13212341 | 0.75 | PTGS2 (0.52) | ALDH1A1CYP2C9CYP2C19PTGS2GLA | |
| SCHEMBL29305591 | 0.75 | ALDH1A1 (0.46) | ALDH1A1CYP2C9CYP2C19PTGS2GLA | |
| SCHEMBL5111012 | 0.74 | LMNA (0.69) | ALDH1A1CYP2C9CYP2C19PTGS2GAA | |
| SCHEMBL15426821 | 0.73 | GAA (0.71) | ALDH1A1CYP2C9CYP2C19PTGS2GLA | |
| SCHEMBL13215281 | 0.72 | ALDH1A1 (0.64) | ALDH1A1CYP2C9CYP2C19PTGS2GLA | |
| SCHEMBL2931027 | 0.72 | ALDH1A1 (0.64) | ALDH1A1CYP2C9CYP2C19PTGS2GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081650-A1 | Antimicrobial Compounds | AXTEN JEFFREY MICHAEL | 2010-04-01 | — | — | US | disclosed |
| US-7622481-B2 | Antibacterial compounds | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| EP-1537123-B1 | AMINO-SUBSTITUTED CYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS | GLAXO GROUP LTD (GB) | 2009-04-29 | — | — | EP | disclosed |
| EP-1399443-B1 | NITROGEN-CONTAINING BICYCLIC HETEROCYCLES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2007-12-12 | — | — | EP | disclosed |
| US-20070135422-A1 | Nitrogen-containing bicycle heterocycles for use as antibacterials | SMITHKLINE BEECHAM P.L.C. | 2007-06-14 | — | — | US | disclosed |
| US-7141564-B2 | Nitrogen-containing bicyclic heterocycles for use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-11-28 | — | — | US | disclosed |
| US-20060189604-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2006-08-24 | — | — | US | disclosed |
| EP-1537123-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-06-08 | — | — | EP | disclosed |
| US-20040171620-A1 | Nitrogen-containing bicyclic heterocycles for use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-09-02 | — | — | US | disclosed |
| EP-1399443-A1 | NITROGEN-CONTAINING BICYCLIC HETEROCYCLES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2004-03-24 | — | — | EP | disclosed |
| WO-2004002992-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-01-08 | — | — | WO | disclosed |
| WO-2003087098-A1 | NITROGEN-CONTAINING BICYCLIC HETEROCYCLES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171620-A1 | Nitrogen-containing bicyclic heterocycles for use as antibacterials | NRDC, NUCB2, NDC1 | ALDH1A1 3787/4885CYP2C9 1505/4885CYP2C19 1343/4885 |
| US-20070135422-A1 | Nitrogen-containing bicycle heterocycles for use as antibacterials | NRDC, NUCB2, NISCH | ALDH1A1 3931/4885CYP2C9 1166/4885CYP2C19 1037/4885 |
| US-20060189604-A1 | Compounds | ELANE, PIGS, SDHA | ALDH1A1 2290/4885CYP2C9 457/4885CYP2C19 633/4885 |
| US-20100081650-A1 | Antimicrobial Compounds | ELANE, NISCH, PIGS | ALDH1A1 2504/4885CYP2C9 1781/4885CYP2C19 1842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.